Medtronic has reported positive results from a study of its MiniMed 780G automated insulin delivery system in addressing burdensome challenges of diabetes.

The data indicates the system's ability in managing hyperglycemia and reducing night-time disruptions for people with type 1 diabetes.

Designed for use by type 1 diabetes patients, the MiniMed 780G system is intended for the continuous delivery of basal insulin at selectable rates and amounts.

The study focused on the dawn phenomenon, a common cause of elevated morning glucose levels.

A retrospective analysis of data from 6,026 patients showed that those switching from the MiniMed 770G to the MiniMed 780G experienced a significant reduction in morning glucose peaks.

The incidence of the dawn phenomenon dropped from 12.2% to 4.5%, and time in range improved from 87.7% to 91.4% between midnight and 6am.

Further data from 8,019 patients, including children under seven, indicated that the MiniMed 780G system's automatic insulin adjustments every five minutes led to fewer overnight interruptions and better glucose control.

Night-time alerts decreased by 45%, and users gained an additional 30–36 minutes of uninterrupted sleep.

Currently, the MiniMed 780G system is available for individuals aged seven and older in more than 100 countries.

Medtronic is also developing the next version of the MiniMed 780G system to further ease diabetes management.

Medtronic Diabetes chief medical officer Robert Vigersky said: “For those living with type 1 diabetes, dawn phenomenon can be a stressful occurrence that feels out of one's control.

“The introduction of the MiniMed 780G system has made it easier to maintain target glucose range with less effort to protect against hyperglycemia. It has been an absolute gift for my patients who have struggled with stubborn highs throughout their diabetes journey.”

In 2022, Health Canada issued a licence to Medtronic’s MiniMed 780G insulin pump system.